secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001193125-25-180890
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd aligns with FDA on rapid BLA pathway for VYD2311; Q2 revenue $11.8M, up 413% YoY
--------------------------------------------------------------------------------

- Q2 2025 PEMGARDA net product revenue $11.8M, up 413% YoY; net loss $14.7M ($0.12/sh) vs $47.2M ($0.40/sh) in Q2 2024.
- Cash and cash equivalents $34.9M as of June 30, 2025; near-term profitability target not met but possible with upcoming season.
- FDA alignment on rapid BLA pathway for VYD2311; single Phase 2/3 trial with 12-week primary endpoint may support approval for COVID-19 prevention.
- Pipeline expansion: RSV candidate identification expected Q3 2025, measles candidate by end of 2025.
- VYD2311 safety data: 76-day half-life IM, attractive profile; quantities of commercial launch product available.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525180890/0001193125-25-180890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312525180890/d936404d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-180890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer